$7.16
0.28%
Nasdaq, Sep 17, 04:00 pm EDT. Closed.
ISIN
US45783C1018
Symbol
TIL

Instil Bio Inc Stock price

$7.21
-0.15 2.04% 1M
-1.36 15.87% 6M
-3.79 34.45% YTD
-14.34 66.54% 1Y
-1.37 15.97% 3Y
-387.99 98.18% 5Y
-392.79 98.20% 10Y
-392.79 98.20% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.03 0.42%
ISIN
US45783C1018
Symbol
TIL
Industry

Is Instil Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$48.7m
Enterprise Value
$64.2m
Net debt
$15.5m
Cash
$69.7m
Shares outstanding
6.8m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.5
Financial Health
Equity Ratio
56.0%
Return on Equity
-
ROCE
-18.5%
ROIC
-
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-35.7m
EBIT
$-36.0m
Net Income
$-30.3m
Free Cash Flow
$-23.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
25.6%
EBIT
28.2%
Net Income
64.2%
Free Cash Flow
52.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-4.5
FCF per Share
$-3.5
Short interest
3.9%
Employees
17
Rev per Employee
-

Instil Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Instil Bio Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Instil Bio Inc forecast:

Buy
71%
Hold
29%

Financial data from Instil Bio Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
38% 38%
-
- Research and Development Expense 14 14
2% 2%
-
-36 -36
26% 26%
-
- Depreciation and Amortization 0.28 0.28
87% 87%
-
EBIT (Operating Income) EBIT -36 -36
28% 28%
-
Net Profit -30 -30
64% 64%
-

In millions USD.

Don't miss a Thing! We will send you all news about Instil Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Instil Bio Inc Stock News

Neutral
GlobeNewsWire
about one month ago
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update. Recent Highlights: Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promis...
Neutral
GlobeNewsWire
4 months ago
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic cand...
Neutral
GlobeNewsWire
6 months ago
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, ...

Company Profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Head office United States
CEO Mr. Crouch
Employees 17
Founded 2018
Website instilbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today